MASSARI, Francesco Saverio
 Distribuzione geografica
Continente #
NA - Nord America 48
Continente sconosciuto - Info sul continente non disponibili 15
EU - Europa 14
AS - Asia 2
Totale 79
Nazione #
US - Stati Uniti d'America 47
IT - Italia 13
BD - Bangladesh 2
CA - Canada 1
GB - Regno Unito 1
Totale 64
Città #
Council Bluffs 21
Milan 5
San Jose 5
Rome 4
Santa Clara 3
Ashburn 2
Los Angeles 2
Tampa 2
Albany 1
Atlanta 1
Barrie 1
Concesio 1
Dallas 1
Genoa 1
Jacksonville 1
London 1
Naples 1
New York 1
Philadelphia 1
Rochester 1
Totale 56
Nome #
Methods to identify molecular expression of mTOR pathway: a rationale approach to stratify patients affected by clear cell renal cell carcinoma for more likely response to mTOR inhibitors 18
Geographical differences in the management of metastatic de novo renal cell carcinoma in the era of immune-combinations 8
Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group? 7
The Tumor Entity Denominated "clear cell-papillary renal cell carcinoma" According to the WHO 2016 new Classification, have the Clinical Characters of a Renal Cell Adenoma as does Harbor a Benign Outcome 7
Global Real-World Outcomes of Patients Receiving Immuno-Oncology Combinations for Advanced Renal Cell Carcinoma: The ARON-1 Study 6
Initial management approach for localized/locally advanced disease is critical to guide metastatic castration-resistant prostate cancer care 6
Clinico-Pathological Features Influencing the Prognostic Role of Body Mass Index in Patients With Advanced Renal Cell Carcinoma Treated by Immuno-Oncology Combinations (ARON-1) 6
Cathepsin K expression in castration-resistant prostate carcinoma: a therapeutical target for patients at risk for bone metastases 6
First-line Systemic Therapy Following Adjuvant Immunotherapy in Renal Cell Carcinoma: An International Multicenter Study 5
Real-world effectiveness of pembrolizumab as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma: the ARON-2 study 4
Application of the Meet-URO score to metastatic renal cell carcinoma patients treated with second- and third-line cabozantinib 2
Prognostic Role of Circulating Tumor Cells in Metastatic Renal Cell Carcinoma: A Large, Multicenter, Prospective Trial 1
Statin use improves the efficacy of nivolumab in patients with advanced renal cell carcinoma 1
Concomitant Use of Statins, Metformin, or Proton Pump Inhibitors in Patients with Advanced Renal Cell Carcinoma Treated with First-Line Combination Therapies 1
Nivolumab VERSUS Cabozantinib as Second-Line Therapy in Patients With Advanced Renal Cell Carcinoma: A Real-World Comparison 1
Totale 79
Categoria #
all - tutte 375
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 375


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2025/20263 0 0 0 0 0 0 0 0 0 0 3 0
2026/202776 17 35 24 0 0 0 0 0 0 0 0 0
Totale 79